A Phase 4 interventional study of bimatoprost 0.01% and travatan 0.004% in Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-30.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing bimatoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Bimatoprost · Glaucoma.
Among the 27 studies testing bimatoprost in Glaucoma, this one is the 17th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2013, is one of 17 in phase 4, and was the 20th registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →None of the 27 studies testing bimatoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →
Bimatoprost: first FDA approval 2001 (LUMIGAN), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 93 is above the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 144 across the 23 interventional studies. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
34 studies in Glaucoma by AbbVie: none open now, none under way, none of them phase 3. Of 33 finished, 23 (70%) have results posted.
Among the 34 studies in Glaucoma by AbbVie, this one is the 25th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2013, is one of 12 in phase 4, and was the 26th registered.
AbbVie’s Glaucoma studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing bimatoprost in Glaucoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 34 in Glaucoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This efficacy and safety study will evaluate LUMIGAN® RC/ LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL MALEATE-EX, 0.5%/TIMOLOL GFS 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
Drug: bimatoprost 0.01% · Drug: hypromellose 0.3%
Travatan 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
Drug: travatan 0.004% · Drug: timolol 0.5%
Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
Also known as: Lumigan® RC, Lumigan®
Travatan 0.004% administered to both eyes once daily for 12 weeks.
Also known as: Travatan Z®
Timolol 0.5% administered to both eyes once daily for 12 weeks.
Also known as: Timolol Maleate-EX, Timolol GFS
Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
Also known as: GenTeal®
Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM
IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) is measured at 8 AM, 12 PM, and 4 PM. IOP is either the average of 2 measurements, or, if a third measurement is required, the average of 3 measurements.
Time frame: Week 12 at 8 AM, 12 PM, and 4 PM
| Milestone | Bimatoprost 0.01% and Hypromellose 0.3% | Travatan 0.004% and Timolol 0.5% |
|---|---|---|
| Started | 47 | 46 |
| Completed | 46 | 44 |
| Not completed | 1 | 2 |
| Withdrew: Non-compliance | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) is measured at 8 AM, 12 PM, and 4 PM. IOP is either the average of 2 measurements, or, if a third measurement is required, the average of 3 measurements.
| Millimeters of Mercury (mmHg) | Bimatoprost 0.01% and Hypromellose 0.3% | Travatan 0.004% and Timolol 0.5% |
|---|---|---|
| Week 12 at 8 AM | 16.4 ± 0.46 | 15.1 ± 0.43 |
| Week 12 at 12 PM | 16.0 ± 0.49 | 15.0 ± 0.38 |
| Week 12 at 4 PM | 16.5 ± 0.48 | 14.5 ± 0.34 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bimatoprost 0.01% and Hypromellose 0.3% | — | 1/47 (2.1%) | 0/47 (0%) |
| Travatan 0.004% and Timolol 0.5% | — | 0/46 (0%) | 0/46 (0%) |
| Event | Bimatoprost 0.01% and Hypromellose 0.3% | Travatan 0.004% and Timolol 0.5% |
|---|---|---|
| Angina PainCardiac disorders | 1/47 | 0/46 |
| Myocardial InfarctionCardiac disorders | 1/47 | 0/46 |
| Age, Continuous(Years) | Bimatoprost 0.01% and Hypromellose 0.3% | Travatan 0.004% and Timolol 0.5% | Total |
|---|---|---|---|
| Mean | 67.8 ± 9.34 | 67.3 ± 8.19 | 67.5 ± 8.74 |
| Sex: Female, Male(Participants) | Bimatoprost 0.01% and Hypromellose 0.3% | Travatan 0.004% and Timolol 0.5% | Total |
|---|---|---|---|
| Female | 24 | 18 | 42 |
| Male | 23 | 28 | 51 |
The record gives a start of Jun 2013, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bimatoprost · Travoprost · Timolol · Hypromellose Derivatives